Connor, Clark & Lunn Investment Management Ltd. Pmv Pharmaceuticals, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $18.8 Billion
- Q3 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Pmv Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 441,024 shares of PMVP stock, worth $657,125. This represents 0.0% of its overall portfolio holdings.
Number of Shares
441,024
Previous 439,139
0.43%
Holding current value
$657,125
Previous $711,000
7.59%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding PMVP
# of Institutions
83Shares Held
41.9MCall Options Held
3.1KPut Options Held
1.7K-
Orbimed Advisors LLC San Diego, CA6.48MShares$9.65 Million0.23% of portfolio
-
Arrow Mark Colorado Holdings LLC Denver, CO3.65MShares$5.43 Million0.08% of portfolio
-
Sio Capital Management, LLC New York, NY3.21MShares$4.79 Million2.53% of portfolio
-
Euclidean Capital LLC New York, NY2.63MShares$3.92 Million0.43% of portfolio
-
Alkeon Capital Management LLC New York, NY2.34MShares$3.49 Million0.01% of portfolio
About PMV Pharmaceuticals, Inc.
- Ticker PMVP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,622,600
- Market Cap $68M
- Description
- PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also d...